{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T16:48:49Z","timestamp":1793810929787,"version":"4.6.1"},"reference-count":38,"publisher":"Informa UK Limited","issue":"15","license":[{"start":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T00:00:00Z","timestamp":1702512000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.2217\/fon-2023-0602","type":"journal-article","created":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T09:23:48Z","timestamp":1702545828000},"page":"969-980","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":69,"title":["HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced\n            <i>EGFR<\/i>\n            -mutated NSCLC after a third-generation EGFR TKI"],"prefix":"10.1080","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8251-0551","authenticated-orcid":false,"given":"Tony","family":"Mok","sequence":"first","affiliation":[{"name":"Department of Clinical Oncology, State Key Laboratory of Translational Oncology &amp; Chinese University of Hong Kong, Hong Kong, Hong Kong PRC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7821-4928","authenticated-orcid":false,"given":"Pasi A","family":"J\u00e4nne","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana-Farber Cancer Institute, Boston, MA02215, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4969-4165","authenticated-orcid":false,"given":"Makoto","family":"Nishio","sequence":"additional","affiliation":[{"name":"Department of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo135-8550, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7653-9748","authenticated-orcid":false,"given":"Silvia","family":"Novello","sequence":"additional","affiliation":[{"name":"Oncology Department at San Luigi Hospital in Orbassano, University of Turin, 10124Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5348-4462","authenticated-orcid":false,"given":"Martin","family":"Reck","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, Airway Research Center North, German Center for Lung Research, LungenClinic, 22927Grosshansdorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6528-6319","authenticated-orcid":false,"given":"Conor","family":"Steuer","sequence":"additional","affiliation":[{"name":"Hematology &amp; Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA30322, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8734-2131","authenticated-orcid":false,"given":"Yi-Long","family":"Wu","sequence":"additional","affiliation":[{"name":"Lung Cancer Institute, Guangdong Province People\u2019s Hospital, Guangzhou, 510317, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0323-1157","authenticated-orcid":false,"given":"Ronan","family":"Fougeray","sequence":"additional","affiliation":[{"name":"Oncology Clinical Development, Daiichi Sankyo Inc, Basking Ridge, NJ07920, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7968-7516","authenticated-orcid":false,"given":"Pang-Dian","family":"Fan","sequence":"additional","affiliation":[{"name":"Oncology Clinical Development, Daiichi Sankyo Inc, Basking Ridge, NJ07920, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6439-7292","authenticated-orcid":false,"given":"Jie","family":"Meng","sequence":"additional","affiliation":[{"name":"Oncology Clinical Development, Daiichi Sankyo Inc, Basking Ridge, NJ07920, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3925-1304","authenticated-orcid":false,"given":"David W","family":"Sternberg","sequence":"additional","affiliation":[{"name":"Oncology Clinical Development, Daiichi Sankyo Inc, Basking Ridge, NJ07920, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Esker","sequence":"additional","affiliation":[{"name":"Oncology Clinical Development, Daiichi Sankyo Inc, Basking Ridge, NJ07920, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0377-9510","authenticated-orcid":false,"given":"Helena A","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Medicine, Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,12,14]]},"reference":[{"key":"e_1_3_9_3_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3002003"},{"key":"e_1_3_9_4_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-2246"},{"key":"e_1_3_9_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810699"},{"key":"e_1_3_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70364-X"},{"key":"e_1_3_9_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909530"},{"key":"e_1_3_9_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.1315"},{"key":"e_1_3_9_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1913662"},{"key":"e_1_3_9_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713137"},{"key":"e_1_3_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.09.009"},{"key":"e_1_3_9_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02641"},{"key":"e_1_3_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00121-7"},{"key":"e_1_3_9_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1612674"},{"key":"e_1_3_9_15_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S157370"},{"issue":"9","key":"e_1_3_9_16_1","first-page":"S1561","article-title":"Nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with EGFR-mutated metastatic non-small-cell lung cancer (mNSCLC) with disease progression after EGFR tyrosine kinase inhibitors (TKIs) in CheckMate 722","volume":"33","author":"Mok TSK","year":"2002","unstructured":"Mok TSK , NakagawaK , ParkKet al. Nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with EGFR-mutated metastatic non-small-cell lung cancer (mNSCLC) with disease progression after EGFR tyrosine kinase inhibitors (TKIs) in CheckMate 722. Ann. Oncol.33(Suppl. 9), S1561\u2013S1562 (2002).","journal-title":"Ann. Oncol."},{"issue":"17","key":"e_1_3_9_17_1","first-page":"abstract LBA900","article-title":"Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: Phase III KEYNOTE-789 study","volume":"41","author":"Yang CH","year":"2023","unstructured":"Yang CH , LeeDH , LeeJSet al. Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: Phase III KEYNOTE-789 study. J. Clin. Onco.41(Suppl. 17), abstract LBA9000 (2023).","journal-title":"J. Clin. Onco."},{"key":"e_1_3_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(23)00135-2"},{"key":"e_1_3_9_19_1","volume-title":"2023 IASLC World Conference on Lung Cancer.","author":"Zhou C","year":"2023","unstructured":"Zhou C , DongX , ChenGet al. IMpower151: phase III study of atezolizumab+bevacizumab+chemotherapy in first-line metastatic nonsquamous NSCLC. Presented at: 2023 IASLC World Conference on Lung Cancer.Republic of Singapore, Singapore (9\u201312 September 2023). Abstract OA09.06."},{"key":"e_1_3_9_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0573-8"},{"key":"e_1_3_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30785-5"},{"key":"e_1_3_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2016.11.008"},{"key":"e_1_3_9_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.77.7326"},{"key":"e_1_3_9_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-020-03239-1"},{"key":"e_1_3_9_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00639-9"},{"key":"e_1_3_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2022.05.011"},{"key":"e_1_3_9_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-43678-6"},{"issue":"2","key":"e_1_3_9_28_1","first-page":"142","article-title":"High c-erbB-3 protein expression is associated with shorter survival in advanced non-small-cell lung carcinomas","volume":"10","author":"Yi ES","year":"1997","unstructured":"Yi ES , HarclerodeD , GondoMet al. High c-erbB-3 protein expression is associated with shorter survival in advanced non-small-cell lung carcinomas. Mod. Pathol.10(2), 142\u2013148 (1997).","journal-title":"Mod. Pathol."},{"key":"e_1_3_9_29_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.18007"},{"key":"e_1_3_9_30_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3359"},{"key":"e_1_3_9_31_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1141478"},{"key":"e_1_3_9_32_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1745"},{"key":"e_1_3_9_33_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-19-0452"},{"key":"e_1_3_9_34_1","doi-asserted-by":"publisher","DOI":"10.1248\/cpb.c18-00744"},{"key":"e_1_3_9_35_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2822"},{"key":"e_1_3_9_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-018-0517-4"},{"key":"e_1_3_9_37_1","volume-title":"American Academy of Cancer Research.","author":"Koyama K","year":"2019","unstructured":"Koyama K , HashimotoY , KamaiYet al. U3-1402, a novel HER3-targeting antibody\u2013drug conjugate, exhibits its antitumor activity through increased payload intracellular delivery via highly efficient internalization. Presented at: American Academy of Cancer Research. (2019)."},{"key":"e_1_3_9_38_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0715"},{"key":"e_1_3_9_39_1","first-page":"JCO2301476","article-title":"HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy","author":"Yu HA","year":"2023","unstructured":"Yu HA , GotoY , HayashiHet al. HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy. J. Clin. Oncol.JCO2301476 (2023).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_9_40_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-1250"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2023-0602","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T14:24:18Z","timestamp":1726755858000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2023-0602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,14]]},"references-count":38,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.2217\/fon-2023-0602"],"URL":"https:\/\/doi.org\/10.2217\/fon-2023-0602","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,14]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-07-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}